T41 mutants of beta-catenin aren't phosphorylated

Stable Identifier
R-HSA-5358752
Type
Pathway
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Summation

T41 mutations of beta-catenin interfere with GSK3 phosphorylation and result in stabilization and nuclear accumulation of the protein (Moreno-Bueno et al, 2002; Taniguchi et al, 2002; reviewed in Polakis, 2012). T41 mutations have been identified in cancers of the liver and brain, as well as in the pituitary, endometrium, large intestine and skin, among others (reviewed in Polakis, 2000; Saito-Diaz et al, 2013).

Literature References
PubMed ID Title Journal Year
10921899 Wnt signaling and cancer

Polakis, P

Genes Dev. 2000
22438566 Wnt signaling in cancer

Polakis, P

Cold Spring Harb Perspect Biol 2012
23256519 The way Wnt works: Components and mechanism

Saito-Diaz, K, Chen, TW, Wang, X, Thorne, CA, Wallace, HA, Page-McCaw, A, Lee, E

Growth Factors 2013
12101426 Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas

Taniguchi, K, Roberts, LR, Aderca, IN, Dong, X, Qian, C, Murphy, LM, Nagorney, DM, Burgart, LJ, Roche, PC, Smith, DI, Ross, JA, Liu, W

Oncogene 2002
12439748 Abnormalities of the APC/beta-catenin pathway in endometrial cancer

Moreno-Bueno, G, Hardisson, D, Sánchez, C, Sarrio, D, Cassia, R, García-Rostán, G, Prat, J, Guo, M, Herman, JG, Matías-Guiu, X, Esteller, M, Palacios, J

Oncogene 2002
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cross References
BioModels Database
Authored
Reviewed